Homologous Recombination Repair Deficiency: An Overview for Pathologists
Details
Publication Year 2023-03,Volume 36,Issue #3,Page 100049
Journal Title
Modern Pathology
Publication Type
Review
Abstract
The repair of DNA double-stranded breaks relies on the homologous recombination repair pathway and is critical to cell function. However, this pathway can be lost in some cancers such as breast, ovarian, endometrial, pancreatic, and prostate cancers. Cancer cells with homologous recombination deficiency (HRD) are sensitive to targeted inhibition of poly-ADP ribose polymerase (PARP), a key component of alternative backup DNA repair pathways. Identifying patients with cancer with HRD biomarkers allows the identification of patients likely to benefit from PARP inhibitor therapies. In this study, we describe the causes of HRD, the underlying molecular changes resulting from HRD that form the basis of different molecular HRD assays, and discuss the issues around their clinical use. This overview is directed toward practicing pathologists wishing to be informed of this new predictive biomarker, as PARP inhibitors are increasingly used in standard care settings.
Publisher
Elsevier
Keywords
Female; Humans; *Recombinational DNA Repair; *Ovarian Neoplasms/genetics; Homologous Recombination; Pathologists; DNA Repair; Hrd; PARPi; clinical sequencing; homologous recombination deficiency; homologous recombination repair; molecular diagnostics
Department(s)
Pathology
PubMed ID
36788098
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-04-06 06:53:44
Last Modified: 2024-07-09 05:22:55

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙